PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

OBJECTIVE: A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER(+)). PARAGON is a basket trial that incorporates 7 phase 2 trials investigating the activity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Peey-Sei, Beale, Philip, O'Connell, Rachel L., Grant, Peter, Bonaventura, Tony, Scurry, James, Antill, Yoland, Goh, Jeffrey, Sjoquist, Katrin, DeFazio, Anna, Mapagu, Cristina, Amant, Frederic, Friedlander, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658604/
https://www.ncbi.nlm.nih.gov/pubmed/31328463
http://dx.doi.org/10.3802/jgo.2019.30.e86

Ejemplares similares

Ejemplares similares